Key Takeaways
- Diversification offsets agro trough: Revenue grew 2% YoY even as DETC sales hit a 7-year low, proving the structural shift toward Performance Solutions, YP derivatives and Contract Manufacturing is working.
- Margins structurally higher: EBITDA margin reached 13.3% (vs 11.1% YoY), driven by mix, procurement timing and cost discipline; management believes current levels are sustainable, with agro recovery offering upside.
- Export engine is real and repeatable: Exports jumped to ₹81 crores from ₹47 crores YoY on new products, customers and geographies, characterized as sustainable growth, not a one-off.
- Balance sheet strength funds the pivot: A net-cash position and ~₹150 crores of committed capex (of a ₹200–300 crore three-year plan) support growth without compromising returns, with a blended ROCE target of 15–20%.
- What to watch next quarter: Whether the planned Q3 Performance Solutions launches land, any progress on the DGTR anti-dumping duty recommendation for organophosphonates, and whether agrochemical intermediates show even tentative signs of a demand floor.
The Diversification Payoff
- Agro hit its floor, the rest carried the quarter: DETC sales fell to their lowest Q2 level in 11 years, driven by Super El Nino and weak demand in India and LATAM. The non-agro portfolio grew enough to deliver overall revenue growth, shifting the agro share to just 35% of H1 revenue.
- Three engines fired simultaneously: Performance Solutions, YP derivatives and Contract Manufacturing all contributed to compensating for the agro shortfall, and management expects them to transition from compensators to standalone growth engines in coming quarters.
- Contract Manufacturing is scaling on plan: Both disclosed active contracts are running at expected capacity, and the quarterly run-rate is on track to reach ₹15 crores on full ramp. Several pipeline opportunities sit at discussion, development or pre-contract stage.
- Performance Solutions adding capacity and products: Additional biocide capacity commissioned in H2 FY26 is fully operational, with new product introductions planned for Q3 and Q4.
- The DETC upcycle, whenever it comes, is pure optionality: The company maintained market share through the downturn and holds very large agrochemical intermediate capacity, so any cycle turn works disproportionately in its favour, though reaching full utilization will take longer than for smaller competitors.
Shroff: "We have delivered a robust performance in Q2 and H1 of FY27. This was despite significant underperformance of DETC in Q2, with quarterly sales at lowest level in the last 7 years. This shows a structural shift in our business model that makes our business more robust."
Margin Architecture
- Gross margin crossed 50% on mix and procurement: Improved product mix toward higher-margin Contract Manufacturing and Performance Solutions, plus timely procurement of raw materials amid volatility, lifted gross margins to ~51%. Lower-cost inventory carried on the balance sheet also helped.
- Sequential EBITDA dip is inventory math, not structural: Gross margin improved sequentially to 50.6%, but EBITDA margin fell from 14.4% to 13.3% because lower-cost inventory is being replaced by higher-cost inventory and the product mix shifted unfavorably as agro intermediates weakened further.
- Inventory build is deliberate, not a red flag: Standalone inventory rose from ₹129 crores (March) to ~₹262 crores (September) as the company built critical raw material buffers to maintain supply continuity and control costs amid price volatility and availability challenges. This inventory supported the improved gross margins.
- Cost pressures persist into H2: Raw material price volatility, supply availability and shipping disruptions are expected to continue through Q3 and Q4; the company will attempt to pass through pricing as much as possible.
Shroff: "On a structural basis we believe we'll be able to sustain these margins. There could be short-term pressures on certain products, and as I shared earlier, depending on the recovery cycle of agrochemicals, if it turns in our favour, of course we can see even better growth, and maybe hopefully bottom line also could improve substantially from here."
Export Growth: The New Leg
- Exports nearly doubled YoY: Export revenue rose to ₹81 crores from ₹47 crores, driven by Performance Solutions and Contract Manufacturing. Management explicitly characterized this as sustainable growth built on new products, new customers and breakthroughs in new geographies, not a one-off order.
- The 5-year supply arrangement is now at full stream: Dedicated capacity for the long-term supply arrangement announced in November 2025 was completed on 23 July 2026, on schedule, and supplies are now running at full volume.
- Contract Manufacturing agreement progressing as contracted: Regular supplies under the May 2024 agreement with a multinational company continue to move per the contract terms.
Shroff: "This is actually a growth which is expected to be sustainable growth, not a one-off single order kind of growth. And this is also largely due to some of the new products we have introduced, new customers that we've been able to obtain, as well as certain new geographies we've been able to make breakthroughs in."
Capital Allocation & Returns Framework
- Disciplined guardrails are explicit: Management targets a fixed asset turnover ratio of 1.5–2x on new capital deployment and a blended ROCE of 15–20%, preferably closer to 20%. Some products may come in below, others above, but the blended outcome is the commitment.
- Capex plan is already substantially committed: Of the ₹200–300 crore three-year plan, approximately ₹150 crores is already committed. New opportunities must be EBITDA-accretive and meet the return thresholds.
- Growth funded internally: The company will fund growth largely from internal accruals and the existing balance sheet, with no indication of needing external capital.
- Silox India investment is acknowledged but unscripted: Management stated the board and management are aware and seized of the matter, and any decision will be communicated at the appropriate time. The company's growth plans are not being compromised by this holding.
Shroff: "From an ROCE perspective, we will be targeting, anywhere 15% to 20% ROCE closer to 20% preferably. In some cases, this is blended I'm talking. Some products may give better ROCE, some products, will come slightly below. But on a blended basis, this is what we are looking at from an ROCE perspective."
Regulatory Catalyst: Anti-Dumping Duty
- DGTR recommendation is in play: The DGTR has recommended anti-dumping duties on HEDP and ATMP (organophosphonates). The recommendation is published but still must go through the next phase before taking effect.
- Pricing upside if implemented: Management has reason to believe domestic pricing will definitely improve if the duty goes into effect, and domestic players are expected to capitalize fully.
- Circumvention risk acknowledged but unaddressed: An analyst flagged that duties on acids only could lead to circumvention via imports in salt or formulation form. Management acknowledged interchangeability is possible and said any circumvention will need to be dealt with appropriately, but offered no specifics.
Near-Term Headwinds & Recovery Signals
- Agro weakness persists into Q3: Agrochemical demand is expected to remain subdued in the near term, with demand weakness likely to persist in Q3, which is seasonally a dip quarter for agrochemical intermediates post-monsoon.
- No full-fledged recovery visible yet: Shipping from China has become difficult, restricting competition to domestic players, but a clear recovery in agrochemical intermediates is not yet visible going into Q3.
- Capacity utilization will lag any recovery: The company holds very large capacity in agrochemical intermediates, so reaching full utilization will take longer than for competitors with lower capacity, even once demand turns.
Gattu: "We have a much larger capacity in the agrochemical intermediates that we are talking about. The, we have a very large capacity, so reaching the full capacity utilization for us will take a longer time vis-a-vis someone who is having a lower capacity."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Performance Solutions launches | New products in Performance Solution range on track | Q3 FY27 |
| YP derivatives launch | New product in YP derivative range targeted | Q4 FY27 |
| Contract Manufacturing run-rate | Reach ₹15 crores per quarter on full ramp of both active contracts | On track (no date given) |
| Capex returns | 1.5–2x fixed asset turnover; 15–20% blended ROCE, closer to 20% | On new capital deployment |
| Margin sustainability | On a structural basis we believe we'll be able to sustain these margins; short-term pressures possible on certain products | Ongoing |
| Agro demand | Demand weakness likely to persist | Near term / Q3 |
| Raw material cost pressure | Price volatility and shipping disruptions may continue to create cost pressure | H2 FY27 |
Key Metrics
| Metric | Q2 FY27 |
|---|---|
| Revenue | ₹274.6 cr, +1.6% YoY |
| EBITDA | ₹36.6 cr, +21.5% YoY |
| EBITDA margin | 13.3%, vs 11.1% in Q2 FY26 |
| PAT | ₹26.7 cr, +42% YoY |
| Gross margin | 50.6%, improved sequentially |
| H1 FY27 revenue | ₹568.3 cr, -2% vs H1 FY26 |
| H1 FY27 EBITDA margin | 13.9%, vs 12.5% in H1 FY26 |
| H1 FY27 PAT | ₹55.8 cr, profit margin of 9.8% |
| Exports | ₹81 cr, vs ₹47 cr in Q2 FY26 |
| H1 revenue mix: agro / non-agro | 35% / 65% |
| DETC quarterly sales | Lowest level in 7 years |
| Inventory | ~₹262 cr (Sep), up from ₹129 cr in Mar |
| Capex plan over 3 years | ₹200–300 cr, ~₹150 cr committed |
| ROCE target on new investments | 15–20%, closer to 20% on blended basis |
| EcoVadis Sustainability rating | Silver, 93rd percentile globally |